<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38257782</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>04</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">82</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16010082</ELocationID><Abstract><AbstractText>Coagulation disorders are described in COVID-19 and long COVID patients. In particular, SARS-CoV-2 infection in megakaryocytes, which are precursors of platelets involved in thrombotic events in COVID-19, long COVID and, in rare cases, in vaccinated individuals, requires further investigation, particularly with the emergence of new SARS-CoV-2 variants. CD147, involved in the regulation of inflammation and required to fight virus infection, can facilitate SARS-CoV-2 entry into megakaryocytes. MCT4, a co-binding protein of CD147 and a key player in the glycolytic metabolism, could also play a role in SARS-CoV-2 infection. Here, we investigated the susceptibility of megakaryocytes to SARS-CoV-2 infection via CD147 and MCT4. We performed infection of Dami cells and human CD34<sup>+</sup> hematopoietic progenitor cells induced to megakaryocytic differentiation with SARS-CoV-2 pseudovirus in the presence of AC-73 and syrosingopine, respective inhibitors of CD147 and MCT4 and inducers of autophagy, a process essential in megakaryocyte differentiation. Both AC-73 and syrosingopine enhance autophagy during differentiation but only AC-73 enhances megakaryocytic maturation. Importantly, we found that AC-73 or syrosingopine significantly inhibits SARS-CoV-2 infection of megakaryocytes. Altogether, our data indicate AC-73 and syrosingopine as inhibitors of SARS-CoV-2 infection via CD147 and MCT4 that can be used to prevent SARS-CoV-2 binding and entry into megakaryocytes, which are precursors of platelets involved in COVID-19-associated coagulopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spinello</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>National Center for Drug Research and Evaluation, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saulle</LastName><ForeName>Ernestina</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6681-6887</Identifier><AffiliationInfo><Affiliation>National Center for Drug Research and Evaluation, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quaranta</LastName><ForeName>Maria Teresa</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>National Center for Drug Research and Evaluation, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelosi</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelli</LastName><ForeName>Germana</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3593-1230</Identifier><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerio</LastName><ForeName>Annamaria</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquini</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3484-6288</Identifier><AffiliationInfo><Affiliation>Core Facilities, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morsilli</LastName><ForeName>Ornella</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular, Endocrine-Metabolic Diseases and Ageing, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>National Center for Drug Research and Evaluation, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labbaye</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Center for Drug Research and Evaluation, Istituto Superiore di Sanit&#xe0;, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NA</GrantID><Agency>Istituto Superiore di Sanit&#xe0;</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000709216">AC-73</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010636">Phenols</NameOfSubstance></Chemical><Chemical><RegistryNumber>8B1QWR724A</RegistryNumber><NameOfSubstance UI="D012110">Reserpine</NameOfSubstance></Chemical><Chemical><RegistryNumber>PPG46JF0EG</RegistryNumber><NameOfSubstance UI="C084824">syrosingopine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008533" MajorTopicYN="Y">Megakaryocytes</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010636" MajorTopicYN="Y">Phenols</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012110" MajorTopicYN="Y">Reserpine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD147</Keyword><Keyword MajorTopicYN="N">MCT4</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">coagulation disorders</Keyword><Keyword MajorTopicYN="N">megakaryocytes</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38257782</ArticleId><ArticleId IdType="pmc">PMC10818282</ArticleId><ArticleId IdType="doi">10.3390/v16010082</ArticleId><ArticleId IdType="pii">v16010082</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239&#x2013;1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020;383:2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cron R.Q., Caricchio R., Chatham W.W. Calming the cytokine storm in COVID-19. Nat. Med. 2021;27:1674&#x2013;1675. doi: 10.1038/s41591-021-01500-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01500-9</ArticleId><ArticleId IdType="pubmed">34480126</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinayagam S., Sattu K. SARS-CoV-2 and coagulation disorders in different organs. Life Sci. 2020;260:118431. doi: 10.1016/j.lfs.2020.118431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118431</ArticleId><ArticleId IdType="pmc">PMC7490584</ArticleId><ArticleId IdType="pubmed">32946915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzaroni M.G., Piantoni S., Masneri S., Garrafa E., Martini G., Tincani A., Andreoli L., Franceschini F. Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. Blood Rev. 2021;46:100745. doi: 10.1016/j.blre.2020.100745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2020.100745</ArticleId><ArticleId IdType="pmc">PMC7444609</ArticleId><ArticleId IdType="pubmed">32868115</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapkiewicz A.V., Mai X., Carsons S.E., Pittaluga S., Kleiner D.E., Berger J.S., Thomas S., Adler N.M., Charytan D.M., Gasmi B., et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine. 2020;24:100434. doi: 10.1016/j.eclinm.2020.100434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100434</ArticleId><ArticleId IdType="pmc">PMC7316051</ArticleId><ArticleId IdType="pubmed">32766543</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Subaie A.M. Coagulopathies in novel coronavirus (SARS-CoV-2) pandemic: Emerging evidence for hematologists. Saudi J. Biol. Sci. 2021;28:956&#x2013;961. doi: 10.1016/j.sjbs.2020.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjbs.2020.11.006</ArticleId><ArticleId IdType="pmc">PMC7642728</ArticleId><ArticleId IdType="pubmed">33169062</ArticleId></ArticleIdList></Reference><Reference><Citation>Elahi S. Hematopoietic responses to SARS-CoV-2 infection. Cell Mol. Life Sci. 2022;79:187. doi: 10.1007/s00018-022-04220-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-022-04220-6</ArticleId><ArticleId IdType="pmc">PMC8918078</ArticleId><ArticleId IdType="pubmed">35284964</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzanelli M.G., Distratis P., Dipalma G., Vimercati L., Inchingolo A.D., Lazzaro R., Aityan S.K., Maggiore M.E., Mancini A., Laforgia R., et al. SARS-CoV-2 Virus Infection May Interfere CD34+ Hematopoietic Stem Cells and Megakaryocyte-Erythroid Progenitors Differentiation Contributing to Platelet Defection towards Insurgence of Thrombocytopenia and Thrombophilia. Microorganisms. 2021;9:1632. doi: 10.3390/microorganisms9081632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9081632</ArticleId><ArticleId IdType="pmc">PMC8400074</ArticleId><ArticleId IdType="pubmed">34442710</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Levy J.H. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc. Med. 2022;32:249&#x2013;256. doi: 10.1016/j.tcm.2022.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8861143</ArticleId><ArticleId IdType="pubmed">35202800</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning J.S., Flight K.E., Higham S.L., Wang Z., Pierce B.F. Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 2021;21:626&#x2013;636. doi: 10.1038/s41577-021-00592-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00592-1</ArticleId><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein N.P., Lewis N., Goddard K., Fireman B., Zerbo O., Hanson K.E., Donahue J.G., Kharbanda E.O., Naleway A., Nelson J.C., et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021;326:1390&#x2013;1399. doi: 10.1001/jama.2021.15072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.15072</ArticleId><ArticleId IdType="pmc">PMC8511971</ArticleId><ArticleId IdType="pubmed">34477808</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Estep B.K., Kuhlmann C.J., Osuka S., Suryavanshi G.W., Nagaoka-Kamata Y., Samuel C.N., Blucas M.T., Jepson C.E., Goepfert P.A., Kamata M. Skewed fate and hematopoiesis of CD34+ HSPCs in umbilical cord blood amid the COVID-19 pandemic. iScience. 2022;25:105544. doi: 10.1016/j.isci.2022.105544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105544</ArticleId><ArticleId IdType="pmc">PMC9650991</ArticleId><ArticleId IdType="pubmed">36406860</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen S., Zhang J., Fang Y., Lu S., Wu J., Zheng X., Deng F. SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism. J. Hematol. Oncol. 2021;14:72. doi: 10.1186/s13045-021-01082-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-021-01082-6</ArticleId><ArticleId IdType="pmc">PMC8082485</ArticleId><ArticleId IdType="pubmed">33926500</ArticleId></ArticleIdList></Reference><Reference><Citation>Maugeri N., De Lorenzo R., Clementi N., Antonia Diotti R., Criscuolo E., Godino C., Tresoldi C., Angels for Covid-BioB Study Group B. Bonini C., Clementi M., et al. Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19. J. Thromb. Haemost. 2022;20:434&#x2013;448. doi: 10.1111/jth.15575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15575</ArticleId><ArticleId IdType="pmc">PMC8646617</ArticleId><ArticleId IdType="pubmed">34710269</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444&#x2013;1448. doi: 10.1126/science.abb2762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2762</ArticleId><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Wang Y., Luo W., Huang L., Xiao J., Li F., Qin S., Song X., Wu Y., Zeng Q. A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells. Int. J. Med. Sci. 2020;17:1522&#x2013;1531. doi: 10.7150/ijms.46695.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.46695</ArticleId><ArticleId IdType="pmc">PMC7359402</ArticleId><ArticleId IdType="pubmed">32669955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemi S., L&#xf3;pez-Mu&#xf1;oz A.D., Holl&#xfd; J., Jin L., Yewdell J.W., Dolan B.P. Variations in Cell Surface ACE2 Levels Alter Direct Binding of SARS-CoV-2 Spike Protein and Viral Infectivity: Implications for Measuring Spike Protein Interactions with Animal ACE2 Orthologs. J. Virol. 2022;96:e0025622. doi: 10.1128/jvi.00256-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00256-22</ArticleId><ArticleId IdType="pmc">PMC9472623</ArticleId><ArticleId IdType="pubmed">36000847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K., Ant&#xf3;n-Pl&#xe1;garo C., Shoemark D.K., Sim&#xf3;n-Gracia L., Bauer M., Hollandi R., et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370:861&#x2013;865. doi: 10.1126/science.abd3072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3072</ArticleId><ArticleId IdType="pmc">PMC7612957</ArticleId><ArticleId IdType="pubmed">33082294</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramatsu T. Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. J. Biochem. 2016;159:481&#x2013;490. doi: 10.1093/jb/mvv127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jb/mvv127</ArticleId><ArticleId IdType="pmc">PMC4846773</ArticleId><ArticleId IdType="pubmed">26684586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Chen W., Zhang Z., Deng Y., Lian J.Q., Du P., Wei D., Zhang Y., Sun X.X., Gong L., et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target. Ther. 2020;5:283. doi: 10.1038/s41392-020-00426-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00426-x</ArticleId><ArticleId IdType="pmc">PMC7714896</ArticleId><ArticleId IdType="pubmed">33277466</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenizia C., Galbiati S., Vanetti C., Vago R., Clerici M., Tacchetti C., Daniele T. SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2. Cells. 2021;10:1434. doi: 10.3390/cells10061434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061434</ArticleId><ArticleId IdType="pmc">PMC8226513</ArticleId><ArticleId IdType="pubmed">34201214</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl T., Kaur I., Aleya L., Sehgal A., Singh S., Sharma N., Bhatia S., Al-Harrasi A., Bungau S. CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target. Sci. Total Environ. 2022;808:152072. doi: 10.1016/j.scitotenv.2021.152072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2021.152072</ArticleId><ArticleId IdType="pmc">PMC8634688</ArticleId><ArticleId IdType="pubmed">34863742</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong L., Edwards C.K., 3rd, Zhou L. The biological function and clinical utilization of CD147 in human diseases: A review of the current scientific literature. Int. J. Mol. Sci. 2014;15:17411&#x2013;17441. doi: 10.3390/ijms151017411.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms151017411</ArticleId><ArticleId IdType="pmc">PMC4227170</ArticleId><ArticleId IdType="pubmed">25268615</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinello I., Saulle E., Quaranta M.T., Pasquini L., Pelosi E., Castelli G., Ottone T., Voso M.T., Testa U., Labbaye C. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. Haematologica. 2019;104:973&#x2013;985. doi: 10.3324/haematol.2018.199661.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.199661</ArticleId><ArticleId IdType="pmc">PMC6518905</ArticleId><ArticleId IdType="pubmed">30467201</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuli&#xe1;-Peris L., Carreres-Rey C., Gabasa M., Alcaraz J., Carretero J., Pereda J. Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play. Int. J. Mol. Sci. 2022;23:6894. doi: 10.3390/ijms23136894.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23136894</ArticleId><ArticleId IdType="pmc">PMC9267107</ArticleId><ArticleId IdType="pubmed">35805895</ArticleId></ArticleIdList></Reference><Reference><Citation>Butera A., Quaranta M.T., Crippa L., Spinello I., Saulle E., Di Carlo N., Campanile D., Boirivant M., Labbaye C. CD147 Targeting by AC-73 Induces Autophagy and Reduces Intestinal Fibrosis Associated with TNBS Chronic Colitis. J. Crohns Colitis. 2022;16:1751&#x2013;1761. doi: 10.1093/ecco-jcc/jjac084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjac084</ArticleId><ArticleId IdType="pmc">PMC9683082</ArticleId><ArticleId IdType="pubmed">35833587</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., von Brunn A., Zhu D. Cyclophilin A and CD147: Novel therapeutic targets for the treatment of COVID-19. Med. Drug Discov. 2020;7:100056. doi: 10.1016/j.medidd.2020.100056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medidd.2020.100056</ArticleId><ArticleId IdType="pmc">PMC7364167</ArticleId><ArticleId IdType="pubmed">32835213</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras-Baeza Y., Sandoval P.Y., Alarc&#xf3;n R., Galaz A., Cort&#xe9;s-Molina F., Alegr&#xed;a K., Baeza-Lehnert F., Arce-Molina R., Guequ&#xe9;n A., Flores C.A., et al. Monocarboxylate transporter 4 (MCT4) is a high affinity transporter capable of exporting lactate in high-lactate microenvironments. J. Biol. Chem. 2019;294:20135&#x2013;20147. doi: 10.1074/jbc.RA119.009093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.009093</ArticleId><ArticleId IdType="pmc">PMC6937558</ArticleId><ArticleId IdType="pubmed">31719150</ArticleId></ArticleIdList></Reference><Reference><Citation>Icard P., Lincet H., Wu Z., Coquerel A., Forgez P., Alifano M., Fournel L. The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. Biochimie. 2021;180:169&#x2013;177. doi: 10.1016/j.biochi.2020.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2020.11.010</ArticleId><ArticleId IdType="pmc">PMC7659517</ArticleId><ArticleId IdType="pubmed">33189832</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S.M., Rosenthal D.S., Greeley T.A., Tantravahi R., Handin R.I. Characterization of a new megakaryocytic cell line: The Dami cell. Blood. 1988;72:1968&#x2013;1977. doi: 10.1182/blood.V72.6.1968.1968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V72.6.1968.1968</ArticleId><ArticleId IdType="pubmed">3196874</ArticleId></ArticleIdList></Reference><Reference><Citation>Besancenot R., Roos-Weil D., Tonetti C., Abdelouahab H., Lacout C., Pasquier F., Willekens C., Rameau P., Lecluse Y., Micol J.B., et al. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood. 2014;124:2104&#x2013;2115. doi: 10.1182/blood-2014-03-559815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-03-559815</ArticleId><ArticleId IdType="pmc">PMC4186539</ArticleId><ArticleId IdType="pubmed">25143485</ArticleId></ArticleIdList></Reference><Reference><Citation>Mardente S., Mari E., Massimi I., Tafani M., Guerriero R., Morsilli O., Pulcinelli F.M., Bianchi M.E., Zicari A. From Human Megakaryocytes to Platelets: Effects of Aspirin on High-Mobility Group Box 1/Receptor for Advanced Glycation End Products Axis. Front. Immunol. 2018;8:1946. doi: 10.3389/fimmu.2017.01946.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01946</ArticleId><ArticleId IdType="pmc">PMC5770369</ArticleId><ArticleId IdType="pubmed">29375570</ArticleId></ArticleIdList></Reference><Reference><Citation>Saulle E., Guerriero R., Petronelli A., Coppotelli E., Gabbianelli M., Morsilli O., Spinello I., Pelosi E., Castelli G., Testa U., et al. Autocrine role of angiopoietins during megakaryocytic differentiation. PLoS ONE. 2012;7:e39796. doi: 10.1371/journal.pone.0039796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039796</ArticleId><ArticleId IdType="pmc">PMC3391299</ArticleId><ArticleId IdType="pubmed">22792187</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Z.G., Wang L., Cui H.Y., Peng J.L., Wang S.J., Geng J.J., Liu J.D., Feng F., Song F., Li L., et al. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget. 2016;7:9429&#x2013;9447. doi: 10.18632/oncotarget.6990.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6990</ArticleId><ArticleId IdType="pmc">PMC4891050</ArticleId><ArticleId IdType="pubmed">26882566</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin D., Robay D., Hindupur S.K., Pohlmann J., Colombi M., El-Shemerly M.Y., Maira S.M., Moroni C., Lane H.A., Hall M.N. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells. Cell Rep. 2018;25:3047&#x2013;3058. doi: 10.1016/j.celrep.2018.11.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.11.043</ArticleId><ArticleId IdType="pmc">PMC6302548</ArticleId><ArticleId IdType="pubmed">30540938</ArticleId></ArticleIdList></Reference><Reference><Citation>Saulle E., Spinello I., Quaranta M.T., Pasquini L., Pelosi E., Iorio E., Castelli G., Chirico M., Pisanu M.E., Ottone T., et al. Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells. Front. Oncol. 2021;10:621458. doi: 10.3389/fonc.2020.621458.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.621458</ArticleId><ArticleId IdType="pmc">PMC7892602</ArticleId><ArticleId IdType="pubmed">33614502</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Cai J., Zhang S., Yuan N., Li X., Fang Y., Song L., Shang M., Liu S., Zhao W., et al. Loss of autophagy leads to failure in megakaryopoiesis, megakaryocyte differentiation, and thrombopoiesis in mice. Exp. Hematol. 2015;43:488&#x2013;494. doi: 10.1016/j.exphem.2015.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exphem.2015.01.001</ArticleId><ArticleId IdType="pubmed">25591498</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun R.J., Shan N.N. Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy. Cancer Cell Int. 2019;19:59. doi: 10.1186/s12935-019-0779-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-019-0779-0</ArticleId><ArticleId IdType="pmc">PMC6419848</ArticleId><ArticleId IdType="pubmed">30923461</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.Z., Xu M., Pradhan M., Gorshkov K., Petersen J.D., Straus M.R., Zhu W., Shinn P., Guo H., Shen M., et al. Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. ACS Pharmacol. Transl. Sci. 2020;3:1165&#x2013;1175. doi: 10.1021/acsptsci.0c00112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.0c00112</ArticleId><ArticleId IdType="pmc">PMC7586456</ArticleId><ArticleId IdType="pubmed">33330839</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M., Baryshnikova E., Anguissola M., Pugliese S., Falco M., Menicanti L. The Long Term Residual Effects of COVID-Associated Coagulopathy. Int. J. Mol. Sci. 2023;24:5514. doi: 10.3390/ijms24065514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24065514</ArticleId><ArticleId IdType="pmc">PMC10049638</ArticleId><ArticleId IdType="pubmed">36982589</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh D., Lim J.C.T., Ferna&#xed;ndez S.B., Joseph C.R., Edwards S.G., Neo Z.W., Lee J.N., Caballero S.G., Lau M.C., Yeong J.P.S. Case report: Persistence of residual antigen and RNA of SARS-CoV-2 virus in tissues of two patients with long COVID. Front. Immunol. 2022;13:1036894. doi: 10.3389/fimmu.2022.1036894.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1036894</ArticleId><ArticleId IdType="pmc">PMC9583834</ArticleId><ArticleId IdType="pubmed">36275692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F., Catalan P., Rodriguez-Grande C., Adan J., Rodriguez-Gonzalez C., Mu&#xf1;oz P., Aldamiz T., Diez C., Perez L., Fanciulli C., et al. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect. Dis. 2022;22:211. doi: 10.1186/s12879-022-07153-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Violi F., Pastori D., Cangemi R., Pignatelli P., Loffredo L. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. Thromb. Haemost. 2020;120:949&#x2013;956. doi: 10.1055/s-0040-1710317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1710317</ArticleId><ArticleId IdType="pmc">PMC7295290</ArticleId><ArticleId IdType="pubmed">32349133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Yu C., Jing H., Wu X., Novakovic V.A., Xie R., Shi J. Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation. Front. Cell. Infect. Microbiol. 2022;12:861703. doi: 10.3389/fcimb.2022.861703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.861703</ArticleId><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaid Y., Guessous F. The ongoing enigma of SARS-CoV-2 and platelet interaction. Res. Pr. Thromb. Haemost. 2022;6:e12642. doi: 10.1002/rth2.12642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12642</ArticleId><ArticleId IdType="pmc">PMC8787413</ArticleId><ArticleId IdType="pubmed">35106430</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefran&#xe7;ais E., Ortiz-Munoz G., Caudrillier A., Mallavia B., Liu F., Sayah D.M., Thornton E.E., Headley M.B., David T., Coughlin S.R., et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544:105&#x2013;109. doi: 10.1038/nature21706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21706</ArticleId><ArticleId IdType="pmc">PMC5663284</ArticleId><ArticleId IdType="pubmed">28329764</ArticleId></ArticleIdList></Reference><Reference><Citation>Pariser D.N., Hilt Z.T., Ture S.K., Blick-Nitko S.K., Looney M.R., Cleary S.J., Roman-Pagan E., Saunders J., 2nd, Georas S.N., Veazey J., et al. Lung megakaryocytes are immune modulatory cells. J. Clin. Investig. 2021;131:e137377. doi: 10.1172/JCI137377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137377</ArticleId><ArticleId IdType="pmc">PMC7773372</ArticleId><ArticleId IdType="pubmed">33079726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelon L., Fromont L., Lefran&#xe7;ais E. Occurrence and role of lung megakaryocytes in infection and inflammation. Front. Immunol. 2022;13:1029223. doi: 10.3389/fimmu.2022.1029223.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1029223</ArticleId><ArticleId IdType="pmc">PMC9745136</ArticleId><ArticleId IdType="pubmed">36524131</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzmann D., Noethel M., Ungern-Sternberg S.V., Mitroulis I., Gawaz M., Chavakis T., May A.E., Seizer P. CD147 is a Novel Interaction Partner of Integrin &#x3b1;M&#x3b2;2 Mediating Leukocyte and Platelet Adhesion. Biomolecules. 2020;10:541. doi: 10.3390/biom10040541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10040541</ArticleId><ArticleId IdType="pmc">PMC7226095</ArticleId><ArticleId IdType="pubmed">32252487</ArticleId></ArticleIdList></Reference><Reference><Citation>Merezhinskaya N., Ogunwuyi S.A., Fishbein W.N. Expression of monocarboxylate transporter 4 in human platelets, leukocytes, and tissues assessed by antibodies raised against terminal versus pre-terminal peptides. Mol. Genet. Metab. 2006;87:152&#x2013;161. doi: 10.1016/j.ymgme.2005.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2005.09.029</ArticleId><ArticleId IdType="pubmed">16403666</ArticleId></ArticleIdList></Reference><Reference><Citation>Aibibula M., Naseem K.M., Sturmey R.G. Glucose metabolism and metabolic flexibility in blood platelets. J. Thromb. Haemost. 2018;16:2300&#x2013;2314. doi: 10.1111/jth.14274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14274</ArticleId><ArticleId IdType="pubmed">30151891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni P.P., Tiwari A., Singh N., Gautam D., Sonkar V.K., Agarwal V., Dash D. Aerobic glycolysis fuels platelet activation: Small-molecule modulators of platelet metabolism as anti-thrombotic agents. Haematologica. 2019;104:806&#x2013;818. doi: 10.3324/haematol.2018.205724.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2018.205724</ArticleId><ArticleId IdType="pmc">PMC6442984</ArticleId><ArticleId IdType="pubmed">30381300</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>